Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashley Grossman

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
International Journal of Endocrinology|April 25, 2022
A Comparison of the Blood Glucose, Growth Hormone, and Cortisol Responses to Two Doses of Insulin (0.15 U/kg vs. 0.10 U/kg) in the Insulin Tolerance Test: A Single-Centre Audit of 174 CasesPhillip Yeoh, Andrew A Dwyer, Ella Anghel, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK CentersMetaxia Tampourlou, Georgia Ntali, Shahzada Ahmed, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2025
A novel molecular imaging technique using [<sup>68</sup>Ga]Ga-mDesmo PET-CT for localizing tumors in Cushing's diseaseRama Walia, Ananda Mohan Chakraborty, Somit Pandey, et al.
Plos One|August 12, 2017
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line modelsSvenja Nölting, Jakob Rentsch, Helma Freitag, et al.
Neuroendocrinology|January 4, 2005
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotidePhilippe Ruszniewski, Sofia Ish-Shalom, Machteld Wymenga, et al.
The Lancet. Diabetes & Endocrinology|July 5, 2022
Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillanceRoss Hamblin, Ashley Vardon, Josephine Akpalu, et al.
The Journal of Clinical Endocrinology and Metabolism|September 10, 2015
Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 PatientsEleni Daniel, Simon Aylwin, Omar Mustafa, et al.
Endocrine Connections|September 2, 2016
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementKjell Oberg, Eric Krenning, Anders Sundin, et al.
Plos Genetics|August 17, 2005
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomasPatricia L M Dahia, Ken N Ross, Matthew E Wright, et al.
Clinical Endocrinology|March 11, 2022
Postradioiodine Graves' management: The PRAGMA studyPetros Perros, Ansu Basu, Kristien Boelaert, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
International Journal of Endocrinology|April 25, 2022
A Comparison of the Blood Glucose, Growth Hormone, and Cortisol Responses to Two Doses of Insulin (0.15 U/kg vs. 0.10 U/kg) in the Insulin Tolerance Test: A Single-Centre Audit of 174 CasesPhillip Yeoh, Andrew A Dwyer, Ella Anghel, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK CentersMetaxia Tampourlou, Georgia Ntali, Shahzada Ahmed, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2025
A novel molecular imaging technique using [<sup>68</sup>Ga]Ga-mDesmo PET-CT for localizing tumors in Cushing's diseaseRama Walia, Ananda Mohan Chakraborty, Somit Pandey, et al.
Plos One|August 12, 2017
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line modelsSvenja Nölting, Jakob Rentsch, Helma Freitag, et al.
Neuroendocrinology|January 4, 2005
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotidePhilippe Ruszniewski, Sofia Ish-Shalom, Machteld Wymenga, et al.
The Lancet. Diabetes & Endocrinology|July 5, 2022
Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillanceRoss Hamblin, Ashley Vardon, Josephine Akpalu, et al.
The Journal of Clinical Endocrinology and Metabolism|September 10, 2015
Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 PatientsEleni Daniel, Simon Aylwin, Omar Mustafa, et al.
Endocrine Connections|September 2, 2016
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementKjell Oberg, Eric Krenning, Anders Sundin, et al.
Plos Genetics|August 17, 2005
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomasPatricia L M Dahia, Ken N Ross, Matthew E Wright, et al.
Clinical Endocrinology|March 11, 2022
Postradioiodine Graves' management: The PRAGMA studyPetros Perros, Ansu Basu, Kristien Boelaert, et al.
Pageof 11